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Background: The survival of malaria parasites, under substantial haem-induced oxidative stress in the red blood
cells (RBCs) is dependent on the pentose phosphate pathway (PPP). The PPP is the only source of NADPH in the
RBC, essential for the production of reduced glutathione (GSH) and for protection from oxidative stress. Glucose-6-
phosphate dehydrogenase (G6PD) deficiency, therefore, increases the vulnerability of erythrocytes to oxidative
stress. In Plasmodium, G6PD is combined with the second enzyme of the PPP to create a unique bifunctional
enzyme, named glucose-6-phosphate dehydrogenase–6-phosphogluconolactonase (G6PD-6PGL). RRx-001 is a novel,
systemically non-toxic, epigenetic anticancer agent currently in Phase 2 clinical development for multiple tumour
types, with activity mediated through increased nitric oxide (NO) production and PPP inhibition. The inhibition of
G6PD and NO overproduction induced by RRx-001 suggested its application in cerebral malaria (CM).
Methods: Plasmodium berghei ANKA (PbA) infection in C57BL/6 mice is an experimental model of cerebral malaria
(ECM) with several similar pathological features to human CM. This study uses intravital microscopy methods with a
closed cranial window model to quantify cerebral haemodynamic changes and leukocyte adhesion to endothelial
cells in ECM.
Results: RRx-001 had both single agent anti-parasitic activity and significantly increased the efficacy of artemether.
In addition, RRx-001 preserved cerebral perfusion and reduced inflammation alone or combined with artemether.
RRx-001’s effects were associated with inhibition of PPP (G6PD and G6PD-6PGL) and by improvements in
microcirculatory flow, which may be related to the NO donating properties of RRx-001.
Conclusion: The results indicate that RRx-001 could be used to potentiate the anti-malarial action of artemisinin,
particularly on resistant strains, and to prevent infection.
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Cerebral malaria (CM) is the most severe neurological
complication of malarial infection. CM is a leading cause
of neurodisability and death [1]. As a multisystem and
multiorgan disease, a range of clinical symptoms charac-
terizes CM, they include unarousable coma, encephalop-
athy, seizures, severe anemia and metabolic acidosis [1–3].
Its pathogenesis is quite complex and involves a cascading
interaction between the parasitized red blood cells (RBCs),* Correspondence: pcabrales@ucsd.edu
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duced regional, or even global, cerebral blood flow with
stagnation hypoxia and neurologic sequelae, inflammatory
responses, breakdown of the blood brain barrier and cere-
bral microhaemorrhages [1, 4, 5].
The malarial parasitic protozoan, Plasmodium falcip-
arum, inextricably linked with humanity since the dawn of
time and the evolutionary driving force behind sickle cell
disease, thalassaemias and G6PD deficiency, and respon-
sible for more than a million deaths every year, remains an
elusive therapeutic target [6]. The high mortality rate is
partly due to the lateness of presentation i.e. after the de-
velopment of loss of consciousness or coma, and is aicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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rapid diagnosis and treatment. An increasing prevalence
of resistance to anti-malarial drugs and a relative dearth of
active agents compound the problem: adjuvant therapy
clinical trials with mannitol, steroids, antipyretics, anti-
seizure control, pentoxifylline, and deferoxamine, among
others, have yielded disappointing results [7].
Cellular redox reactions play important roles not only
in redox regulatory processes and antioxidant defense,
but also in the mechanisms of drug action and drug re-
sistance in malaria parasites. Recent advances in parasite
biology suggest a compartmentalization of redox metab-
olism and cellular processes that are sites of drug action
[8, 9]. The pentose phosphate pathway (PPP) of both the
host RBCs and the parasite are crucial to neutralize dele-
terious reactive oxygen species (ROS) that accumulate
during RBC parasite infection and from haemoglobin
(Hb) degradation [10]. Since RBCs lack mitochondria,
the PPP is the only pathway in these cells to generate
NADPH, which acts as the main reducing equivalent,
contributing to the maintenance of reduced glutathione
(GSH) [11]. As a result, the PPP of erythrocytes is highly
up-regulated after Plasmodium infection, due to high
oxidative stress requiring NADPH redox power for anti-
oxidant systems, and the need for ribose 5-phosphate to
synthesize nucleotides for cell growth [12]. On the other
hand, the first two steps of the PPP in the parasites (P.
falciparum, Plasmodium berghei, Plasmodium knowlesi,
Plasmodium yoelii and Plasmodium chabaudi) are cata-
lyzed by a bifunctional enzyme, glucose-6-phosphate
dehydrogenase-6-phosphogluconolactonase (G6PD-6PGL)
[13]. While a Krebs cycle is present and functional in the
malaria parasite, glucose flux through it is reduced and de-
pends on the developmental stage of the parasite [14]. By
contrast, glucose utilization through glycolysis and PPP in-
creases ~70-fold with P. falciparum infection and, remark-
ably, the enhancement in activity is primarily due to
activation of the parasite PPP [15].
C57BL/6 mice infected with P. berghei, strain ANKA
(PbA), develop neurological symptoms (ataxia, progres-
sive paralysis, hypothermia, seizure, coma) characteristic
of a syndrome known as experimental cerebral malaria
(ECM) [16]. Intravital microscopy, which allows direct ob-
servation of the live brain in real time through a closed cra-
nial window model, is unsurpassed in terms of the ability
to explore the cerebral microvasculature during disease
progression [17–20]. The cortical microcirculation shares
the same general behaviour and functionality of the brain
circulation, including the blood—brain barrier properties
[21]. ECM pathogenesis is associated with microcirculatory
complications, similar to that observed in parenchymal
vessels, including decreased blood flow, vasoconstriction,
and vascular plugging by adherent cells and microhaemor-
rhages [18–20].RRx-001 is a redox-active epigenetic anticancer agent in
Phase 2 clinical trials with p53 and Nrf2-mediated neuro-
protective properties (unpublished data P. Cabrales) and
potential anti-sickling capabilities [22]. RRx-001 selectively
binds to the β-cysteine 93 residue on Hb [23]. Although
Hb is not technically an enzyme, it functions as a nitrite
(NO2
−) reductase, reducing nitrite into nitric oxide (NO) in
the presence of hypoxia [24]. Binding of RRx-001 to the β-
cysteine 93 residue allosterically increases inherent Hb
nitrite reductase functionality to overproduce NO, specif-
ically under hypoxic conditions [25].
The present study defines the efficacy of RRx-001,
artemether, and a combination of artemether-RRx-001
in a murine model of P. berghei ECM as determined by
(i) P. berghei parasitaemia kinetics with treatment start-
ing on day 7 post infection (ii) survival of mice and (iii)
motor performance of mice with late-stage ECM. In
addition, this study evaluates the in vitro effect of RRx-
001 on G6PD activity, the in vitro anti-malarial activity
of RRx-001, and its limited haemolytic effects.
Methods
Blood collection
Blood collection was approved by the Institutional Animal
Care and Use Committee, and was conducted accordingly
to the Guide for the Care and Use of Laboratory Animals
(US National Research Council, 2010). Blood was obtained
from donor mice (C57BL/6, ~25 g). Animals were anaes-
thetized (pentobarbital 60 mg/kg ip) and a femoral cath-
eter (PE-50) was implanted and blood was drawn into
syringes containing ACD (38 mM citric acid, 75 mM so-
dium citrate, 136 mM glucose) as the anticoagulant. The
cells were pelleted, buffy coat was discarded to remove the
leukocytes, and the erythrocytes were washed three times
(RPMI 1640 supplemented with 27 mM NaHCO3, 25 mM
HEPES, 0.35 mM hypoxanthine). The washed RBCs were
then resuspended in RPMI 1640 with 0.5 % albumin solu-
tion. Asexual stages of P. berghei were cultured in vitro
and synchronized by sorbitol [26]. Briefly, the cells were
harvested when maximum infected RBCs (iRBCs) were
predominantly rings, washed and treated with 5 % sorbitol
(in double distilled water) at 37 °C for 10 min, washed re-
peatedly with RPMI 1640, and subcultured with RBCs
prepared as described above. Parasites were maintained at
5 % haematocrit at 37 °C in a humidified chamber
containing 5 % CO2.
In vitro glucose consumption
IRBCs were harvested, washed and resuspended at 50 %
haematocrit in RPMI 1640. Glucose consumption was de-
termined by incubating 1 mL aliquots of IRBCs (trophozo-
ite stage) and uninfected RBCs at 37 °C. Glucose
concentration in those aliquots was increased by adding
glucose solution to 12 mM. Samples (100 μL) were taken
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after adding glucose, and plasma separated by centrifuging
at 10,000 g for 2 min. Glucose concentration was deter-
mined using a YSI 2300 STAT Plus (YSI, Yellow Springs,
Ohio) and glucose consumption was calculated from a lin-
ear regression of glucose concentration versus time. For
glucose consumption of free parasites, the IRBCs (tropho-
zoite stage) were treated with Sendai virus (Sigma-Aldrich).
Briefly, iRBCs (5 % haematocrit) were incubated with
Sendai virions (40 μg/mL) for 7 min. IRBC, uninfected
RBCs and free trophozoite parasites were also evaluated in
medium containing 0.5 mM methylene blue (MB).
Closed cranial window animal preparation
Animal handling and care followed the NIH Guide for
Care and Use of Laboratory Animals. All protocols were
approved by the Institutional Animal Care and Use
Committee, and conducted accordingly to the Guide for
the Care and Use of Laboratory Animals (US National
Research Council, 2010). Eight to 10-week old C57Bl/6
(Jackson Laboratories, ME) were implanted with a closed
cranial window model as described elsewhere [27]. Briefly,
mice were anesthetized with ketamine-xylazine and were
administered dexamethasone (0.2 mg/kg), carprofen
(5 mg/Kg) and ampicillin (6 mg/kg) subcutaneously, in
order to prevent post-surgical swelling of the brain, in-
flammatory response and infection. After shaving the head
and cleansing with ethanol 70 % and betadine, the mouse
was placed on a stereotaxic frame and the head immobi-
lized using ear bars. The scalp was removed with sterilized
surgical instruments; lidocaine-epinephrine was applied
on the periosteum, which was then retracted to expose the
skull. A 3–4 mm diameter skull opening was made in the
left parietal bone using a surgical drill. Under a drop of sa-
line, the craniotomy was lifted away from the skull with
very thin tip forceps and gelfoam previously soaked in sa-
line applied to the dura mater in order to stop any even-
tual small bleeding. The exposed area was covered with a
5 mm glass cover slip secured with cyanocrylate-based
glue and dental acrylic. Carprofen and ampicillin were
given daily for 3–5 days after recovery from surgery. Mice
presenting signs of pain or discomfort were euthanized
with 100 mg/kg of euthasol IP. Two-three weeks after sur-
gery, mice fulfilling the inclusion criteria (see below) were
inoculated with P. berghei ANKA and, on day 6 of infec-
tion, they were lightly anesthetized with isoflurane (4 %
for induction, 1–2 % for maintenance) and held on a
stereotaxic frame for measurements of pH and PO2.
Inclusion criteria
Animals were suitable for the experiments if: 1) animal
behaviour was normal and; 2) microscopic (x350 magni-
fication) examination of the cranial window did not re-
veal signs of edema or bleeding.Parasite infection
Animals were inoculated with an IP injection of 1 × 106
P. berghei ANKA parasites expressing the green fluores-
cent protein (PbA-GFP, a donation from the Malaria
Research and Reference Reagent Resource Center – MR4,
Manassas, VA). Parasitaemia, body weight, rectal
temperature and clinical status (using six simple tests
adapted from the SHIRPA protocol, as previously de-
scribed) were monitored daily from day 4 of the infection
[28]. Parasitaemia was checked using flow cytometry by
detecting the number of fluorescent GFP-expressing
pRBCs in relation to 10,000 RBCs. ECM was diagnosed
when one or more of the following clinical signs of neuro-
logical involvement were observed: ataxia, limb paralysis,
poor righting reflex, seizures, roll-over or coma.Experimental groups
At day 7, P. berghei-infected mice presenting poor right-
ing reflex, hypothermia and/or other clinical signs of
neurological involvement such as ataxia, limb paralysis,
seizures and/or roll-over were randomly assigned to the
four different treatment therapies. Group 1: Untreated
animals. Group 2: Animals were treated with the experi-
mental agent, RRx-001 (EpicentRx, Inc Mountain View,
CA) IV at 10 mg/kg. Group 3: Animals were treated with
artemether (Artesiane, Dafra Pharma, Belgium) IP at
50 mg/kg. Group 4: Animals were treated with arte-
mether IP at 50 mg/kg and RRx-001 IV at 10 mg/kg.
Treatments were given every other day starting on day 7
after infection until day 12 after infection. Parasitaemia,
motor behaviour and rectal temperature were checked
at each time point and daily afterwards. After treatment,
parasitaemia was checked by microscopical examination
of Giemsa-stained blood smears to differentiate viable
from dead parasites.Experimental set-up
Animals were lightly anesthetized with isoflurane (4 %
for induction, 1–2 % for maintenance). They were se-
cured to the microscopic stage of an intravital micro-
scope (BX51WI, Olympus, New Hyde Park, NY) on a
stereotaxic frame with the head gently held with ear bars
for epi-illumination imaging. Body temperature, mea-
sured pre-anesthesia, was maintained with a heating
pad. The tissue image was projected onto a charge-
coupled device camera (COHU 4815) connected to a
videocassette recorder and viewed on a monitor. Mea-
surements were carried out using a 40X (LUMPFL-WIR,
numerical aperture 0.8, Olympus) water immersion ob-
jective. The animals did not recover from anesthesia, be-
ing euthanized (Euthasol 100 mg/kg, IP) right after the
intra vital microscopy measurements.
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A video image-shearing method was used to measure
vessel diameter (D) [29]. Changes in arteriolar and venu-
lar diameter from baseline were used as indicators of a
change in vascular tone. Arteriolar and venular center-
line velocities were measured on-line using the photo-
diode cross-correlation method (Photo Diode/Velocity
Tracker Model 102B, Vista Electronics, San Diego, CA).
The measured centerline velocity (V) was corrected ac-
cording to vessel size to obtain the mean RBC velocity
[30]. Blood flow (Q) was calculated from the measured
values as Q = π × V (D/2)2. This calculation assumes a
parabolic velocity profile and has been found to be ap-
plicable to tubes of 15–80 μm internal diameters and for
Hcts in the range of 6–60 % [30].
Endothelial leukocyte adhesion
The closed cranial window model was used as previously
described [19]. On day 8 after P. berghei infection, anti-
CD45-TxR antibodies (CalTag, Carlsbad, CA; 4 μg) were
intravenously infused through the tail vein (volume:
50 μL). Using water-immersion objectives (20X), blood
vessel images were captured using a CCD camera
(COHU 4815, San Diego, CA). Fifteen minutes after in-
jection red (615 nm) fluorescently labeled leukocytes
were excited and images were captured with a Vivid
Standard: XF42 filter. Adherence was defined as cells
remaining static for 30 s. For each selected vessel, Added
leukocytes were quantified in a 100 μm length sections.
Haematocrit and haemoglobin
Blood was collected from the tail in heparinized glass ca-
pillaries. Haemoglobin was determined spectrophoto-
metrically from a single drop of blood B-haemoglobin
(Hemocue, Stockholm, Sweden). Haematocrit was esti-
mated by centrifugation.
In vitro drug sensitivity testing
A series of experiments were conducted to evaluate the
anti-malarial activity of RRx-001 on blood stage malaria
parasites using P. berghei in mice RBCs. Infected RBCs
from a continuous in vitro culture of asexual erythrocyte
stages of P. berghei were used for the anti-malarial assay.
[31]. Different doses of RRx-001 and positive controls,
chloroquine diphosphate (Sigma-Aldrich, St. Louis, MO)
and artemether (Artesiane®, Dafra Pharma, Belgium),
were incubated with the parasites for 72 h followed by
detection of growth inhibition using the DNA binding
dye SYBR green [32, 33]. Briefly, 20 μL of 10X SYBR
Green I nucleic acid gel stain (Sigma-Aldrich), 0.5 % v/v
Triton, and 0.5 mg/mL saponin solution were added per
80 uL of treated infected RBCs per well. Assay plates
were shaken for 30 s, incubated in the dark for 4 h, and
then read with on a using a microplate reader (SynergyHT, Bio-Tek Instruments, Inc., Winooski, VT) at Ex/Em
485 nm/535 nm. EC50s were calculated using GraphPad
Prism 6 (GraphPad Software, Inc., San Diego, CA).
G6PD activity
Cell free extracts were used for measuring G6PD activ-
ity. Dehydroepiandrosterone (DHEA, Sigma-Aldrich) a
potent uncompetitive inhibitor of mammalian G6PD
was used as positive control. HEP-G2 cells (hepatocellu-
lar carcinoma, ATCC, Manassas, VA) were seeded and
when the cells were about 60–70 % confluent, the
medium from each flask was discarded, and the attached
cells were rinsed twice with phosphate buffered saline
(PBS). Cells were then harvested and centrifuged in PBS.
Aliquots were used for determination of protein concen-
tration, following bicinchoninic acid (BCA) protein assay
(Pierce Biotech. Inc). Cell extract was incubated in a
final volume of 150 μL of 100 mM potassium phosphate
buffer (pH 7.4) containing a NADPH generating system.
The reaction was started by the addition of 20 μL of cell
extracts to 980 μL of 0.1 M Tris–HCl buffer (pH 8.1)
containing 1 M MgCl2,10 mM NADP, 200 mM glucose-
6-phosphate, and testing compounds (RRx-001 and
DHEA). These mixtures were incubated at room
temperature. Rate of NADPH formation was determined
using the absorption at 340 nm (Lambda 20, Perkin-
Elmer, Foster City, CA). The result was expressed as a
percentage of the control activity measured with the cell
extract incubated in the presence of DMSO.
Haemolytic activity in uninfected mice
Nine (n = 9) uninfected mice were treated with RRx-001
(EpicentRx, Inc.) IV at 10 mg/kg (n = 3), artemether
(Dafra Pharma) IP at 50 mg/kg (n = 3), or artemether IP
at 50 mg/kg and RRx-001 IV at 10 mg/kg (n = 3). Blood
was collected before treatment, 24 h and 48 h after treat-
ment from the tail in heparinized glass capillaries.
Data analysis
Results are presented as mean ± standard deviation, ex-
cept for vessel diameters and blood flows. Data between
groups was analysed by an analysis of variance (ANOVA,
Kruskal-Wallis test). When appropriate, post hoc analyses
were performed with the Dunns multiple comparison test.
All statistics were calculated using GraphPad Prism 6
(GraphPad Software, Inc., San Diego, CA). Changes were
considered statistically significant if P < 0.05.
Results
RRx-001 is a potent inhibitor of G6PD
Given the tropism of RRx-001 for the RBC and the de-
pendence of the malaria parasite on the PPP, the effects of
RRx-001 on 6GPD of RBCs, infected RBCs, and parasites




Fig. 1 a. Illustration of glycolytic metabolic fluxes during normal conditions. Previous studies indicate that the PPP uses 30 % of the glucose
consumed by the RBC [43]. b. Illustration of glycolytic metabolic fluxes during increased PPP flux resulting from methylene blue. The response of
the RBC PPP to methylene blue has been widely used to demonstrate the presence of PPP in RBC [44]. c. Glucose consumption of Plasmodium
berghei ANKA (PbA) infected RBCs, uninfected RBCs and free parasites. Parasitaemia was 10 % of the infected RBC. Glucose utilization of infected
RBCs was 35 times higher than uninfected RBCs. Free parasites accounted for the increased in glucose consumption. Glucose consumption
during increased PPP flux with methylene blue (MB, 5 mM) augmented glucose utilization of uninfected RBCs by 80 % compared to control
conditions. Infected RBCs increased PPP flux in response to MB by more than 120 %, and the free parasite increased PPP flux in response to MB
by 100 %. Therefore, the parasite and infected RBCs have large capacity to deal with oxidative stress, and the uninfected RBCs to preserve
reduced Hb and GSH. d. Glucose consumption of Plasmodium berghei ANKA infected RBCs, uninfected RBCs and free parasites treated with
20 μM RRx-001. RRx-001 reduced glucose utilization of uninfected, infected RBCs and parasites. RRx-001 also prevented the drastic increase in
glucose consumption during of increased PPP flux with MB (5 mM). Although, MB still increased the glucose utilization of RRx-001 treated
uninfected RBCs by 35 %, in the infected RBCs by 55 %, and in the free parasite by 80 %, respectively. Therefore, RRx-001 reduced the capacity
of parasites, infected RBCs and uninfected RBCs to deal with oxidative stress, and to preserve reduced Hb and GSH
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to untreated infected cells, indicating inhibition of the PPP
(Fig. 1d). 5 mM methylene blue, which stimulates PPP
flux, did not increase glucose utilization of treated cells in
combination with RRx-001 (Fig. 1c and 1d). Infected RBCs
presented a significantly increased glucose metabolism
compared to uninfected RBCs (Fig. 1). Both glycolysis and
PPP appear to be increased in the infected RBCs. Simi-
larly, previous studies have shown that the ratio of glucose
metabolization through the PPP and glycolysis increases
for infected relative to uninfected RBCs [15]. The glucose
utilization by the infected RBCs in the animals is relatively
small compared to the overall glucose utilization by the
other tissues. However, previous studies have investigated
glucose uptake rates into brain tissue in P. berghei-infected
mice, and found there to be no significant difference in
uptake rates compared with uninfected mice [34].
Adjunctive therapy with RRx-001 improves survival in
mice with late-stage ECM
Starting on day 7 post-infection, every other day treatment
resulted in 83 % survival in the RRx-001 plus artemether-
treated group compared to a 50 % survival in the group re-
ceiving artemether alone. All untreated mice succumbed to
their infection (Fig. 2a). In addition near zero parasitaemia
was observed by Day 11, 4 days after the start of treatment
with the combination of artemether-RRx-001 while parasit-
aemia in mice treated with RRx-001 and artemether mono-
therapy trended towards, but did not quite reach, zero
parasitaemia by Day 12 (Fig. 2b). In the parasite infected
untreated group hyperparasitaemia increased until death.
RRx-001 adjunctive therapy rescues mice with established
clinical signs of motor impairment
Mice infected with PbA exhibit similar neurological im-
pairments to those in P. falciparum infected humans, in-
cluding ataxia, hemiplegias, and seizures (Fig. 2c). As in
humans, survival with ECM does not necessarily correl-
ate with an improvement in neurological impairment.
Therefore, mice were evaluated for motor performance,
starting on Day 7 after infection, with five tests (transfer
arousal, locomotor activity, tail elevation, wire maneuver
and righting reflex) modified from the SHIRPA protocol
[28]. For each test, mice received an individual score,
and the sum of scores was used to create a composite
score. The results (Fig. 2c) demonstrated that by Day 11,
mice treated with the every other day combination of
RRx-001 and artemether, signs of neurological involve-
ment were rapidly responsive and returned to baseline
while the mice treated with artemether alone and RRx-
001 alone improved only slightly and the untreated co-
hort not at all. These data suggest that the combination
of artemether and RRx-001 is neuroprotective and ame-
liorates neurological deficits in murine cerebral malaria.RRx-001 adjunctive treatment decreases inflammation
and prevents severe anaemia
The number of adhered and rolling leukocytes in small ve-
nules on day 8 after infection were quantified using fluor-
escent intra-vital microscopy (Fig. 3a and 3b). All therapies
reduced the number of adhered and rolling leukocytes
compared to untreated mice. Treatment with RRx-001 and
artemether + RRx-001 reduced the number of adhered and
rolling leukocytes compared to artemether alone. All
groups showed decrease haematocrit compared to unin-
fected mice (Fig. 3c). The RRx-001+ artemether combin-
ation prevented the decrease in haematocrit.
RRx-001 adjunctive treatment improves cerebral
haemodynamics
Using intra vital microscopy through a closed cranial
window, pial arteriolar diameters and cerebral blood
flow (RBC velocities) were evaluated in groups of seven
animals. Non-infected control mice showed stable vessel
diameters. All P. berghei-infected mice presented with
vasoconstriction of pial arterioles compared with unin-
fected mice (Fig. 4a). Vessels in untreated mice remained
constricted with a mean decrease in vascular patency of
40 %. By contrast, mice treated with artemether + RRx-
001, artemether alone and RRx-001 alone showed rever-
sal of vasoconstriction relative to the uninfected animals.
All groups showed a mean 40 % decrease in blood flow on
day 7 at the start of treatment (Fig. 4b). The RRx-001+
artemether combination attenuated the decrease in blood
flow in relation to uninfected mice, returning almost to
baseline levels, followed by artemether alone and RRx-001
alone where blood flow remained stable at around 60 % of
baseline. Blood flow in the untreated P. berghei-infected
mice dropped to around 40 % of baseline.
RRx-001 anti-malarial activity, G6PD inhibition and
haemolytic safety
In vitro drug susceptibility of infected mice RBC allowed
to establish dose response for artemether and RRx-001
compared to chloroquine. In vitro drug susceptibility is
presented in Table 1. RRx-001 showed potent anti-
malarial, although as a single agent, the drug sensitivity
testing indicated that higher dose of RRx-001 was required
to inhibited 50 % of the parasite’s activity. RRx-001 effects
on G6PD are presented in Table 2. In comparison to
DHEA, a potent uncompetitive inhibitor of mammalian
G6PD, RRx-001 showed a more potent inhibition at con-
centrations as low as 1 μM. Haemolytic potential of RRx-
001 in uninfected animals was compared to artemether,
and the combination RRx-001 and artemether at the dose
used with the infected mice. Haemolytic potential of RRx-
001 is presented in Table 3. All drugs and their combin-
ation showed mild haemolysis, most probably due to the




Fig. 2 Survival, parasitaemia, and motor score of mice infected with Plasmodium berghei ANKA. Mice were either left untreated (n = 7; white
quare) or were treated with RRx-001 (IV at 10 mg/kg; n = 7 mice; red circle) or artemether (IP at 50 mg/kg; n = 7, blue diamond), or 10 mg/kg IV of
RRx-001 plus 50 mg/kg IP of artemether (n = 7, red circle with blue border). All parameters were measured at the same time points for all groups.
The points were artificially displaced horizontally for clarity. a. Mice survival after infection. These data represent the trajectory of disease. At day 7 post
infection, Kaplan-Meier survival curves were plotted and by day 12 differences in rates of survival in the various groups were observed: RRx-001 plus
artemether 83 %, RRx-001 16.6 %, artemether 50 % and untreated 0 %. b. Mice parasitaemia after infection. Parasitaemia was monitored daily in
surviving mice with Giemsa-stained thin blood smears from day 1 to day 12 post infection, and the mean ± SD for each group is shown. The
parasitaemia peaks for all groups occurred between days 7–9. The parasitaemia in the untreated group increased progressively from the peak,
while RRx-001, artemether decreased to almost zero levels and RRx-001 + artemether reached zero by Day 11. The percent change in parasitaemia after
initiation of treatment with the combination of artemether-RRx-001 reaches 100 %; while artemether alone and RRx-001 approaches did not reach 100
%. c. Neurological motor scores after infection. Motor performance (modified SHIRPA test) for all groups was analysed. Motor behaviour drastically
deteriorated in the untreated group while it rebounded in the treated groups, only returning to baseline i.e. to the level of uninfected groups in the
RRx-001 + artemether cohort
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Malaria is characterized by low NO production and endo-
thelial dysfunction [35]. Conversely, malarial immunity is
associated with high levels of NO [36, 37] and NOdonation with nitroglycerin or L-arginine supplementation
had been shown to partially prevent the development
ECM, decrease vascular pathology, and increase survival




Fig. 3 Beneficial effect of artemether plus RRx-001 treatment in leukocyte adhering and rolling in pial venules from late-stage ECM mice. Groups
are displayed as follows: untreated Plasmodium berghei ANKA infected mice (black), PbA infected mice treated with RRx-001 (IV at 10 mg/kg, red),
PbA infected mice treated with artemether (IP at 50 mg/kg blue) and PbA infected mice treated with 10 mg/kg IV of RRx-001 plus 50 mg/kg IP of
artemether (red with blue border). a. Adhering leukocytes. Leukocyte adhesion in venules was measured (Day 9). b. Rolling leukocytes. Leukocyte
rolling in venules was measured (Day 9). c. Haematocrit after infection. Mice were either left untreated (n = 7; white quare) or were treated with
RRx-001 (IV at 10 mg/kg; n = 7 mice; red circle) or artemether alone (IP at 50 mg/kg; n = 7, blue diamond), or 10 mg/kg IV of RRx-001 plus 50 mg/kg IP
of artemether (n = 7, red circle with blue border). Haematocrit was measured from samples collected from the tail vein. Hct were measured at the same
time points for all groups. The points were artificially displaced horizontally for clarity
Yalcin et al. Malaria Journal  (2015) 14:218 Page 8 of 12previous studies demonstrated the NO donors (such as
NONOates, NO-generating diazeniumdiolate) can prevent
ECM, however high doses are required [18, 20].
RRx-001 has a distinct advantages over nitroglycerin
(and over other systemic vasodilators like nifedipine andA 
Fig. 4 Beneficial effect of artemether plus RRx-001 treatment in pial arterio
untreated (n = 7; white quare) or were treated after day 7 with RRx-001 (IV at 1
blue diamond), or 10 mg/kg IV of RRx-001 plus 50 mg/kg IP of artemether (n =
before infection. Vessel diameter remained unchanged until day 7. Untreated
presented arteriolar vessel diameter compared to untreated. RRx-001 alone an
b. Changes in arteriolar blood flow relative to before infection. Blood flow dec
untreated animals continue decreasing to 20–30 % by day 9 after infection. Tr
exception that RRx-001 in combination with artemether restored blood flow tNONOates) in the clinical setting because RRx-001 me-
diated NO delivery is site-specific under hypoxia; there-
fore, the orthostatic hypotension, tachycardia, headaches
and palpitations associated with nitroglycerin and other ni-
trate esters or the severe hypotensive effects of NONOatesB 
les and blood flow from late-stage ECM mice. Mice were either left
0 mg/kg; n = 7 mice; red circle) or artemether alone (IP at 50 mg/kg; n = 7,
7, red circle with blue border). a. Changes in arteriolar diameter relative to
animals showed rapid progression of vasoconstriction. Treatment
d in combination with artemether prevented the vasoconstriction.
reased to 60 % of before infection by day 7 after infection. Blood flow in
eatment presented blood flow at around 60 % before infection, with the
o 80 % before infection
Table 1 In vitro drug sensitivity testing
Antimalaria activity
IC50 (ug/ml)
RRx-001 0.14 ± 0.04
Artemether 0.09 ± 0.02
Chloroquine 0.05 ± 0.02
IC50 is the concentration inhibiting 50 % of parasite’s activity. Values are
mean ± SD (n = 4)
Table 3 Hemolytic activity in uninfected mice
Hemolytic effects on RRx-001, Artemether, & RRx-001 + Artemether
Hematocrit, % BL Day 1 Day 1
RRx-001 51 ± 2 49 ± 1 49 ± 2
Artemether 51 ± 2 47 ± 2 48 ± 2
RRx-001 + Arthemether 50 ± 2 46 ± 4 47 ± 2
Hematocrit was measured before (baseline, BL) and after single treatment of
un infected mice. Three animals were used in each group. Values are reported
as mean ± SD
Yalcin et al. Malaria Journal  (2015) 14:218 Page 9 of 12do not occur with RRx-001. Safety data from preclinical
studies showed blood pressure changes only at very high
doses (EpicentRx, unpublished data) and it was, therefore,
unnecessary to routinely measure blood pressure in the
Phase I and II trials. In the Phase 1 study, RRx-001 was
well-tolerated, systemically non-toxic and was not associ-
ated with changes in haemoglobin-associated variables
[38]. The present study demonstrates that RRx-001 inhibits
in a dose dependent fashion the PPP (G6PD) of RBCs and
parasites. Analysis of PPP flux revealed that RRx-001 in-
hibits G6PD more effectively than the positive control,
DHEA, a known G6PD inhibitor, preventing conversion of
glucose-6-phosphate to 6-phosphogluconolactone and re-
duction of NADP. The significant G6PD inhibition ob-
served with dose as low as 1 μM, could limits ribose
phosphate, which is necessary for RNA and DNA biosyn-
thesis in the parasite.
Moreover, treatment with systemic NO donors like
nitroglycerin may theoretically lead to cerebral vascular
steal syndrome, paradoxically reducing perfusion to is-
chemic areas and worsening outcome [39], also was not
observed with RRx-001 based in human clinical trials.
Finally, unlike nitroglycerin, RRx-001 has a specific trop-
ism for RBCs where it binds to Hb and glutathione, initi-
ating a subhaemolytic free radical cascade. These ROS
and reactive oxygen nitrogen species (RONS) exacerbate
artemether-induced oxidative injury to the parasite at
the point of origin in the RBC, tipping them over the
edge (Fig. 5) and leads to inhibition of G6PD expression
and activity. Replenishment and restoration of NO pro-
duction “on demand” in hypoxic areas should a) reverse
vasospasm and reduce the sequelae of endothelial dys-
function and b) mediate antiplasmodial toxicity through
the production of inflammatory levels of ROS and RONSTable 2 G6PD Activity
Effects on G6PD inhibition activity
G6PD activity in HEP-G2 (% of control, 182 ± 16 nmol/min/mg of protien)
1 μM 50 μM 100 μM
DHEA 84 ± 7 39 ± 6 11 ± 2
RRx-001 78 ± 6 16 ± 4 6 ± 1
Cell-free extracts were incubated with each drug at concentrations of 1, 10
and 100 μM, and G6PD activities were measured. Dehydroepian drosterone
(DHEA). Data represent the mean ± SD(n = 4)as NO combines with malaria-generated superoxide (O2
−)
in the RBC to form highly reactive, peroxynitrite (ONOO−)
[31, 40]. This reactive free radical, in turn, oxidizes
cysteine-dependent enzymes, G6PD and G6PD-6PGL on
which the parasite is dependent. An overview of RRx-001
on malarial pathogenesis is shown in Fig. 6.
In treating the ECM only after clear signs of neuro-
logical derangement became evident, these studies were
designed to closely mimic the typical presentation of a
cerebral malarial patient, who is more likely to receive
treatment during an advanced disease stage. These data
demonstrate that after infection with P. berghei, RRx-001
in combination with artemether, reversed vasospasm and
improved cerebral perfusion, while significantly decreased
parasitaemia and increased survival. These effects were as-
sociated with the inhibition and down-regulation of G6PD
activity and improved cerebral haemodynamic parameters
with significant recovery of motor scores. RRx-001 has
anti-malarial activity as a single agent and potent G6PD in-
hibition at relatively low dose. As an epigenetic agent,
which chemosensitizes in cancer, RRx-001 may potentiate
the activity of artemether through silencing genes up regu-
lated in responses to stress. Although this hypothesis was
not investigated in the current study, future studies will de-
termine the genes methylated by RRx-001 or its byproducts
that enhanced the effects of conventional anti-malaria treat-
ment (artemether) and provided microvascular protection.
The pathology of CM is clearly multifactorial involving
the interplay of local infection and post-infection sys-
temic complications resulting from aggregation of para-
sitized RBCs, cytokine release and Hb-driven oxidative
damage in the cerebral vasculature. The alleviation of
the parasite burden in CM with artemether does not ne-
cessarily imply protection against long-term neurological
deficits [32], since cerebral ischemia-reperfusion injury
following relief of vascular obstruction may lead to coag-
ulopathy, vasoconstriction, and hypoperfusion. There-
fore, the key to successfully manage CM is to eliminate
or alleviate both the parasitic infection and the vasculop-
athy, consisting of malarial RBC adhesion and vaso-
occlusion. These data suggest that a combination of
RRx-001 with artemether would address both the infec-
tion and the vasculopathy leading to a promising novel
treatment paradigm for CM.
Fig. 5 Graphical abstract of the mouse pial vascular network after infection with P. Berghei / ANKA. a. Progression of cerebral malarial in the
rodent model. Neurological and motor dysfunction correlate with reduced cerebral blood flow and increased inflammation. b. Balance between
pro-oxidant and anti-oxidant determines survival of erythrocytes. Limiting the capacity to deal with oxidative stress by inhibiting G6PD and limiting
NADPH levels with RRx-001, increases efficacy of anti-malarial therapies. Intraerythrocytic malarial parasites are subject to high levels of free radicals due
to the catabolism of Hb. Additional RONS stress from RRx-001 and artemether may tip the parasite over the threshold into death. c. Macroscopic
images of cranial windows from the rodent model. Images are from day 9 after infection. Uninfected animals show normal microcirculation. Artemether
treated animal showed micro-haemorrhages. RRx-001 treated animal showed preserved microcirculation structure. Artemether and RRx-001 treated
animal showed preserved microcirculation structure and microvascular function. Untreated animals showed micro-haemorrhages followed by vasospasms
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tion in malaria. Nearly all evaluated interventions have
been dramatically effective in the murine model, al-
though there is no convincing evidence of benefit for
any adjunctive intervention in human cerebral malaria
[7]. Several cases of haemolysis induced by anti-malarial
therapies have been reported in severe G6PD deficient
patients [6]. Haemolytic potential of RRx-001 in unin-
fected animals was compared to artemether and the
combination RRx-001 and artemether at the dose used
with the infected mice. All drugs and their combination
did not result in haemolytic crisis (Fig. 6c). In erythro-
cytes, G6PD only works at a fraction of its maximum
capacity, because it is inhibited by NADPH under
physiological conditions [8]. Only in severe G6PD-
deficient cells, the NADPH/NADP ratio is lower com-
pared to normal cells and the G6PD activity is closer to
the maximum activity available [41]. It is unlikely thatRRx-001 will produce haemolysis due to G6PD inhib-
ition, because the dose required for treatment only has
limited G6PD inhibition.
Conclusion
In conclusion, in the present study, RRx-001 is an ef-
fective adjunctive therapy for ECM in association with
artemether; this effect was associated with improve-
ment of vascular dysfunction and motor scores. Evi-
dence of frontline-based artemisinin (qinghaosu)
resistance to malaria across Southeast Asia [42] under-
scores the need for an expanded repertoire of anti-
malarials with novel mechanisms of action such as
RRx-001. In addition, since epigenetic agents are asso-
ciated with the reversal of chemoresistance in cancer,
it is also possible that epigenetic agents, like RRx-001,
may have use in malaria and similarly reverse resist-
ance to the anti-malarials currently in use. While these
Fig. 6 Vascular effects of malaria parasitized red blood cells. a. Malaria limits NO bioavailability and RRx-001 restores NO. Malaria is a disease of
low NO bioavailability resulting from both low levels of production and high scavenging rates.[45] Red blood cell (RBC) lysis leads to the release of Hb
and arginase: Acellular Hb scavenges NO and arginase degrades arginine, which is an NO precursor. The consequences of low NO bioavailability are:
less deformable RBCs leading to occlusion, vasospasm and ischemia. As deoxyHb nitrite reductase catalyst, RRx-001 produces NO “on demand” in
ischemic/ hypoxic areas, reversing the vascular defects. b. Proposed vascular status of malaria parasitized RBCs after treatment with RRx-001. Overview
of direct and indirect therapeutic effects of RRx-001 on malarial pathogenesis. RRx-001 affects parasitized RBC directly by increasing of oxidative stress
with resulting G6PD inhibition while indirectly treating vasculopathic sequelae due to low NO bioavailiability. c. G6PD in uninfected and infected RBCs.
In uninfected erythrocytes, G6PD operates at a fraction of its capacity. Under increased oxidative stress, the NADPH is oxidized and G6PD becomes
highly activated. Limiting G6PD lowers the ration NADPH/NADP, increasing G6PD activity. Under conditions of oxidative stress, known to be important
for the action of anti-malarial drugs, cells with limited G6PD can only activate their G6PD activity to a small extent, under the risk of haemolytic anemia.
RBCs and malaria parasites are equipped with antioxidant defense systems, glutathione (GSH) and thioredoxin (Trx) systems, which are both NADPH
dependent. The GSH system reduced GSSG to GSH, using GSH reductase (GR), present in RBCs and malaria parasites. In addition, parasites have
thioredoxin reductase (TR), which reduces Trx disulfide (Trx-S2) to the Trx dithiol-form [Trx-(SH)2]. The PPP is the only source of NADPH in erythrocytes,
and most likely the major source of NADPH in the parasite
Yalcin et al. Malaria Journal  (2015) 14:218 Page 11 of 12results are promising, further studies, especially in
G6PD-deficient models, to support the potential ap-
plicability of RRx-001 as an adjunctive therapy for CM
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